REDWOOD CITY, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Dextera Surgical Inc. (Nasdaq: DXTR ), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that the next-generation MicroCutter 5/80 surgical stapler has now been successfully used to treat 50 patients by leading surgeons around the world.
In thoracic, pediatric, general and urologic surgery cases, surgeons assessed the MicroCutter 5/80’s performance including hemostasis, staple line quality, and procedure-enabling aspects of the device. This assessment demonstrated overall excellent performance, hemostasis and reliability in real-world clinical use in both thin and medium tissue, and further validated the clinical benefits of the MicroCutter 5/80.
Leading surgeons and centers in the U.S. and Europe participated, including Prof. Dr. Johannes Bodner, M.Sc., of Klinikum Bogenhausen, Munich, Germany, and Joel Dunning, M.D., of James Cook University Hospital, Middlesbrough, UK, who used the stapler to perform a variety of surgical procedures.
“The MicroCutter’s low profile and wide articulation allow me to navigate into small spaces better than traditional staplers,” said Prof. Bodner.
“The MicroCutter demonstrated excellent hemostasis,” said Dr. Dunning. “This device has made it easier to perform less-invasive approaches to thoracic surgery including both uniportal and microlobectomy techniques, which lead to reduced pain and shorter hospital stays.”
“We are pleased to have reached this milestone and to now be able to offer both white and blue reloads for thin and medium tissue, which broadens the applicability of the MicroCutter 5/80 to a wider number of procedures,” said Julian Nikolchev, president and CEO, Dextera Surgical. “We are very excited to be working with highly respected pioneers aligned with our goal of enabling cutting-edge procedures that push minimally invasive surgery forward.”
MicroCutter Indication Information The MicroCutter 5/80 Stapler is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. The MicroCutter 30 White Reload has application in vascular tissue.
About Dextera Surgical Dextera Surgical (Nasdaq: DXTR ) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.
The company's signature proprietary technology, the MicroCutter 5/80 Stapler, is the world's first and only five-millimeter surgical stapler that articulates to 80 degrees in each direction. As the smallest-profile articulating stapler available today, the MicroCutter 5/80 Stapler may reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult-to-reach anatomy. The cartridge-based device's small size and wide articulation range are designed to enhance the surgeon's access and visualization at the surgical site and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices.
Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.
Forward-Looking Statements The statements in this press release regarding the expected benefits of using the MicroCutter 5/80 are "forward-looking statements." There are a number of important factors that could cause actual results to differ materially from those indicated by these forward-looking statements, including those described in Dextera Surgical’s Annual Report on Form 10-K for the year ended June 30, 2016, under the caption “Risk Factors,” filed with the U.S. Securities and Exchange Commission on October 12, 2016. Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov .
Contact: Bob Newell Vice President, Finance and Chief Financial Officer (650) 331-7133 investors@cardica.com Media: Kelly Morrison +1 (224) 240-1481 kelly@kellyamorrison.com
